Product Code: ETC069948 | Publication Date: Jul 2023 | Updated Date: Jan 2024 | Product Type: Report | |
Publisher: 6Wresearch | No. of Pages: 70 | No. of Figures: 35 | No. of Tables: 5 | |
The Philippines biosimilars market is expected to witness a significant growth in the coming years, driven by growing demand for cost-effective biopharmaceuticals. The increasing prevalence of chronic and lifestyle disorders such as cancer, diabetes, cardiovascular diseases and arthritis across the country are likely to drive the demand for biosimilar drugs over the forecast period. Additionally, rising investments from government authorities towards expanding healthcare infrastructure and improving accessibility of affordable medicines will be another key factor fuelling market expansion. Moreover, technological advancements in biologics manufacturing processes are projected to create lucrative opportunities for players operating in this space
Growing collaborations between research organizations and drug manufacturers is anticipated to spur income prospects within the industry over time. Additionally, an Increasing investment from leading pharmaceutical companies towards developing innovative therapies using advanced biological techniques is one of the major trends propelling market advancemenet. Further, the emergence of novel delivery systems such as self-administered injectables/inhalers designed specifically for patient convenience has been gaining traction lately and this trend is expected to continue during 2020-2025 timeline.
High costs associated with development & production process inhibits widespread availability particularly among low income population limit potential customer base restraining sales proportions eventually hampering entire industry progress rate adversely
Major players operating in Philippine biosimilars market include Pfizer Inc., Amgen Inc., Sandoz (Novartis AG), Biocon Ltd., Intas Pharmaceuticals Limited , Reliance Life Sciences Pvt Ltd etc
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Philippines Biosimilars Market Overview |
3.1 Philippines Country Macro Economic Indicators |
3.2 Philippines Biosimilars Market Revenues & Volume, 2020 & 2027F |
3.3 Philippines Biosimilars Market - Industry Life Cycle |
3.4 Philippines Biosimilars Market - Porter's Five Forces |
3.5 Philippines Biosimilars Market Revenues & Volume Share, By Product, 2020 & 2027F |
3.6 Philippines Biosimilars Market Revenues & Volume Share, By Indication, 2020 & 2027F |
3.7 Philippines Biosimilars Market Revenues & Volume Share, By Manufacturing, 2020 & 2027F |
4 Philippines Biosimilars Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Philippines Biosimilars Market Trends |
6 Philippines Biosimilars Market, By Types |
6.1 Philippines Biosimilars Market, By Product |
6.1.1 Overview and Analysis |
6.1.2 Philippines Biosimilars Market Revenues & Volume, By Product, 2018 - 2027F |
6.1.3 Philippines Biosimilars Market Revenues & Volume, By Insulin, 2018 - 2027F |
6.1.4 Philippines Biosimilars Market Revenues & Volume, By Follitropin, 2018 - 2027F |
6.1.5 Philippines Biosimilars Market Revenues & Volume, By Calcitonin, 2018 - 2027F |
6.1.6 Philippines Biosimilars Market Revenues & Volume, By Glucagon, 2018 - 2027F |
6.1.7 Philippines Biosimilars Market Revenues & Volume, By Teriparatide, 2018 - 2027F |
6.1.8 Philippines Biosimilars Market Revenues & Volume, By Others, 2018 - 2027F |
6.2 Philippines Biosimilars Market, By Indication |
6.2.1 Overview and Analysis |
6.2.2 Philippines Biosimilars Market Revenues & Volume, By Oncology, 2018 - 2027F |
6.2.3 Philippines Biosimilars Market Revenues & Volume, By Offsite Treatment, 2018 - 2027F |
6.2.4 Philippines Biosimilars Market Revenues & Volume, By Chronic Disorders, 2018 - 2027F |
6.2.5 Philippines Biosimilars Market Revenues & Volume, By Blood Disorders, 2018 - 2027F |
6.2.6 Philippines Biosimilars Market Revenues & Volume, By Infectious Diseases, 2018 - 2027F |
6.2.7 Philippines Biosimilars Market Revenues & Volume, By Others, 2018 - 2027F |
6.3 Philippines Biosimilars Market, By Manufacturing |
6.3.1 Overview and Analysis |
6.3.2 Philippines Biosimilars Market Revenues & Volume, By Outsourced, 2018 - 2027F |
6.3.3 Philippines Biosimilars Market Revenues & Volume, By In-house, 2018 - 2027F |
7 Philippines Biosimilars Market Import-Export Trade Statistics |
7.1 Philippines Biosimilars Market Export to Major Countries |
7.2 Philippines Biosimilars Market Imports from Major Countries |
8 Philippines Biosimilars Market Key Performance Indicators |
9 Philippines Biosimilars Market - Opportunity Assessment |
9.1 Philippines Biosimilars Market Opportunity Assessment, By Product, 2020 & 2027F |
9.2 Philippines Biosimilars Market Opportunity Assessment, By Indication, 2020 & 2027F |
9.3 Philippines Biosimilars Market Opportunity Assessment, By Manufacturing, 2020 & 2027F |
10 Philippines Biosimilars Market - Competitive Landscape |
10.1 Philippines Biosimilars Market Revenue Share, By Companies, 2020 |
10.2 Philippines Biosimilars Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |